Business
INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS
Grant will fund proof-of-concept studies for XPro1595 therapy LA JOLLA, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an
About this update from Inmune Bio Inc.
[{"type":"text","content":" Grant will fund proof-of-concept studies for XPro1595 therapy\n LA JOLLA, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that reprogram the patient’s innate immune system to fight disease, today announced that it has been awarded a $500,000 grant from The ALS Association. The grant will fund proof-of-concept studies for XPro1595, a novel therapy targeting innate immune dysfunction and chronic inflammation as a cause of Amyotrophic lateral sclerosis (ALS). The endowment was awarded through the Association’s The Lawrence and Isabel Barnett Drug Development Program and will be allocated over two years. “We are honored to receive this grant from The ALS Association, the pre-eminent organization supporting novel treatments for ALS,” said R.J. Tesi, M.D., Chief Executive Officer of INmune Bio. “As an immunology company, we focus on the role that innate immune dysfunction and neuroinflammation play in the progression of neurodegenerative diseases such as ALS. This award supports our approach and moves the company’s ALS program closer to the clinic.” “While our knowledge of ALS has increased dramatically in the past few years, there are currently no disease modifying therapies,” said CJ Barnum, Ph.D., Director of Neuroscience for INmune Bio. “The innate immune system plays a central role in the development and progression of ALS. We believe precision targeting of the innate immune system by targeting inflammation with XPro1595 may be an effective treatment strategy in alleviating ALS. This award allows INmune Bio to take the first step to determine whether XPro1595 has therapeutic potential for ALS patients.” “We believe INmune is on a path to unlocking some of the mystery around the immune system and how it responds to the kinds of inflammation that we know plays a role in ALS progression,” said Kuldip Dave, Ph.D, vice president of research at The ALS Association. “This grant will greatly accelerate proof of concept and advance our knowledge of immune dysfunction and neuroinflammation in people living with ALS.” About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’...